Drug Profile
DAP 30
Latest Information Update: 12 Oct 2000
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antivirals
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 02 Sep 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 01 Feb 1995 Preclinical development for HIV infections treatment in USA (Unknown route)